As shown in Figure 5B, the half‐maximal inhibitory concentration (IC50) of MRTX1719 in MTAP‐deleted glioma cells was significantly lower than that in MTAP‐normal cells, and such a situation will not be different because of different cell lines, which indicated that therapeutic targeting of PRMT5/MTA was a promising strategy to selectively inhibit the proliferation of MTAP‐deficient glioma cells. This evidence concerns the gene MTAP and central nervous system cancer.